Objective To explore the clinical effect of different doses of metformin empagliflozin in patients with type 2 diabetes mellitus.Methods The clinical data of 124 patients with type 2 diabetes mellitus admitted to Shanxian Central Hospital from January 2022 to January 2023 were retrospectively selected.According to the different treat-ment options,the patients were divided into control group(n=62,treated with 0.5 g/time of metformin+5 mg/time of empagliflozin)and study group(n=62,treated with 1.0 g/time of metformin+10 mg/time of empagliflozin).The total ef-fective rate,blood glucose levels,islet function,body mass index and incidence of adverse reactions were compared between the two groups.Results There was no significant difference in the total effective rate between the two groups(P>0.05).After treatment,the fasting plasma glucose,2-hour postprandial plasma glucose and glycated hemoglobin A1c in the study group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The fasting insulin,insulin resistance index and body mass index in the study group were lower than those in the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of type 2 diabetes mellitus,the use of 1.0 g/time of metformin and 10 mg/time of empagliflozin is more effective,which can improve blood glucose levels in a short period of time,regulate blood lipid metabolism,and have more advantages in weight control and higher safety.
Type 2 diabetes mellitusMetforminEmpagliflozinFasting insulinAdverse reaction
维普
万方数据
